Alnylam stock falls on fraud probe

Alnylam Pharmaceuticals’ stock price has been under pressure after the company announced it was lowering its financial forecasts for its most important drug franchise, Amvuttra, by $200 million.

The announcement was made on July 30, 2026, and it had an immediate impact on the stock price, which fell nearly 29% and closed at $211.06, approaching the stock’s 52-week low.

The company’s Q2 earnings were not just disappointing due to missing revenue targets, but they also reflected a more fundamental shift in the market in favor of stabilizers like Vyndamax and Attruby over silencers like Alnylam’s Amvuttra.

Alnylam had predicted that its treatments would bring in $4.4 billion to $4.7 billion by 2026, but the company lowered its full-year revenue guidance to a range of $4.2 billion to $4.5 billion.

This has left investors wondering about the company’s long-term prospects, as the Wainua trial and the lead of stabilizer drugs like BridgeBio’s Attruby have filled the gap in the cardiovascular market.

Analysts raised 2026 worldwide sales projections to over $1 billion for BridgeBio, with peak sales forecast at $3.5 billion.

The Law Offices of Frank R. Cruz, among other firms, opened an investigation into Alnylam Pharmaceuticals on behalf of investors due to concerns that the company possibly violated federal securities laws.

This investigation is attributed to the stock guidance cuts announced on July 30th, followed by the sizable drop in Alnylam’s stock price, which is a common occurrence when a public company makes a significant downward revision to its stock guidance.

The investigation will examine whether management knew or should have known that sales trends were weaker than previously communicated, and regardless of the investigation’s results, Alnylam’s standing in the market has been severely damaged.

The company’s main product, an ATTR-CM silencer, has been significantly undermined, along with investors’ trust in the company, and it is likely that patients and clinicians may be more likely to opt for stabilizer treatments like acoramidis over silencer treatments like Amvuttra.

The failure of AstraZeneca’s Wainua in its clinical trial points to the fact that silencer treatments are no longer the treatment of choice for clinicians.

Alnylam will need to reassess its strategy in the market and consider how to regain the trust of investors and clinicians, as the market is a complex and competitive space.

They must carefully plan their next moves to regain their footing, and for now, the company’s future remains uncertain.

Investors will be closely watching the outcome of the US investigation and the company’s next moves in the market.

One thing is certain, however: the company’s financial difficulties are likely not merely a short-term price fluctuation, but a long-term structural issue.